Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.

Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.
复制标题

DOI:
10.1021/jm201376w
复制
发表时间:
2012-03-08
影响因子:
7.3
通讯作者:
Marshall, Fiona H.
Marshall, Fiona H.
中科院分区:
医学1区
文献类型:
--
作者:
Congreve, Miles;Andrews, Stephen P.;Dore, Andrew S.;Hollenstein, Kaspar;Hurrell, Edward;Langmead, Christopher J.;Mason, Jonathan S.;Ng, Irene W.;Tehan, Benjamin;Zhukov, Andrei;Weir, Malcolm;Marshall, Fiona H.

文献摘要

参考文献

被引文献

相似文献

使用基于结构的药物设计方法,已鉴定出有效的、配体有效的、选择性的且口服有效的1,2,4-三嗪衍生物作为腺苷A2 A受体的拮抗剂。结合到GPCR的化合物4 e和4g的X射线晶体结构说明分子在正构结合腔内部深深结合。化合物4k的体内药代动力学和功效数据,证明了这一系列化合物用于治疗帕金森病的潜力。
Potent, ligand efficient, selective, and orally efficacious 1,2,4-triazine derivatives have been identified using structure based drug design approaches as antagonists of the adenosine A2A receptor. The X-ray crystal structures of compounds 4e and 4g bound to the GPCR illustrate that the molecules bind deeply inside the orthosteric binding cavity. In vivo pharmacokinetic and efficacy data for compound 4k are presented, demonstrating the potential of this series of compounds for the treatment of Parkinson’s disease.
DOI: 10.1021/jm00145a002
发表时间: 1985-01-01
影响因子: 7.3
作者:
GOODFORD, PJ
通讯作者: GOODFORD, PJ
DOI: 10.1021/ja076498n
发表时间: 2007-12-19
影响因子: 15
作者:
Murphy, Jaclyn M.;Liao, Xuebin;Hartwig, John F.
通讯作者: Hartwig, John F.
DOI: 10.1016/s0040-4039(02)01135-8
发表时间: 2002-08-05
影响因子: 1.8
作者:
Takagi, J;Sato, K;Miyaura, N
通讯作者: Miyaura, N
DOI: 10.1038/nature10136
发表时间: 2011-05-18
期刊: NATURE
影响因子: 64.8
作者:
Lebon, Guillaume;Warne, Tony;Edwards, Patricia C.;Bennett, Kirstie;Langmead, Christopher J.;Leslie, Andrew G. W.;Tate, Christopher G.
通讯作者: Tate, Christopher G.